GPC3 and hepatocellular carcinoma: In conclusion, while GPC-3 may have limited value as a single time-point measurement for predicting HCC development in patients with HCV-related cirrhosis after SVR to DAA therapy, our findings support its potential role as a diagnostic and prognostic biomarker, particularly for risk stratification and clinical decision-making after HCC diagnosis.